Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product

• US 5,731,284 A
• Filed: 09/28/1995
• Issued: 03/24/1998
• Est. Priority Date: 09/28/1995
• Status: Expired due to Term

• Current Assignee: Amgen Inc.
• Original Assignee: Amgen Inc.
• Inventors: Williams, Lawrence R.
• Primary Examiner(s): Tsang, Cecilia J.
• Assistant Examiner(s): TOUZEAU, LYNN
• Application Number:
  US08/535,682
• Time in Patent Office: 908 Days
• Field of Search: 514/8, 514/21
• US Class Current: 514/8.4
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

The present invention relates generally to methods for treating injury or degeneration of basal forebrain cholinergic neurons by administering glial cell line-derived neurotrophic factor (GDNF). The invention relates specifically to methods for treating Alzheimer'"'"'s disease.

Claims

1. A method for treating injury or degeneration of basal forebrain cholinergic neurons comprising administering to a subject suffering from such injury or degeneration a therapeutically effective amount of a glial cell line-derived neurotrophic factor (GDNF) protein product.

2. The method of claim 1 wherein the injury or degeneration of basal forebrain cholinergic neurons is associated with Alzheimer'"'"'s disease.

3. The method of claim 1 wherein the GDNF protein product is the amino acid sequence set forth in SEQ ID NO:

1 or a variant, or a derivative thereof.

4. The method of claim 3 wherein the GDNF protein product has the amino acid sequence set forth in SEQ ID NO:

1.

5. The method of claim 3 wherein the GDNF protein product is Met^-1 !GDNF.

6. The method of claim 3 wherein the GDNF protein product comprises a water soluble polymer.

7. The method of claim 6 wherein the water soluble polymer is polyethylene glycol.

8. The method of claim 1 wherein the GDNF protein product is administered at a dose between about 10 μ

g/kg/day and 100 mg/kg/day.

9. The method of claim 1 wherein the GDNF protein product is administered at a dose between about 1 mg/kg/day and 25 mg/kg/day.

10. The method of claim 2 further comprising administering to the patient an effective amount of a second therapeutic agent for Alzheimer'"'"'s disease.

11. The method of claim 10 wherein the second therapeutic agent is selected from the group consisting of cholinesterase inhibitors, nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3), neurotrophin-4/5 (NT-4/5), basic fibroblast growth factor (bFGF), and ciliary neurotrophic factor (CNTF).